GlucoTrack Establishes Patient Advisory Board for CBGM

GlucoTrack ( (GCTK) ) just unveiled an announcement.

On May 20, 2025, Glucotrack, Inc. announced the establishment of a Patient Advisory Board (PAB) to guide the development of its long-term implantable Continuous Blood Glucose Monitor (CBGM). The PAB, consisting of leading patient voices, aims to ensure that patient insights are central to Glucotrack’s development plans. The inaugural meeting took place on May 3, 2025, and the board will regularly provide feedback on diabetes management and product development. Glucotrack’s CBGM is designed for up to three years of continuous monitoring, offering a more convenient solution by measuring glucose directly from blood.

Spark’s Take on GCTK Stock

According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.

GlucoTrack’s overall stock score is significantly impacted by its poor financial performance, characterized by a lack of revenue and negative equity. However, positive corporate events, including strategic partnerships and clinical advancements, provide some optimism. The technical analysis and valuation further emphasize the company’s current challenges, with bearish trends and poor valuation metrics. While speculative interest might arise from recent developments, the stock remains under pressure due to financial instability.

To see Spark’s full report on GCTK stock, click here.

More about GlucoTrack

Glucotrack, Inc. (NASDAQ: GCTK) is a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing a long-term implantable continuous blood glucose monitoring system that offers continuous monitoring without a wearable component.

Average Trading Volume: 5,936,335

Technical Sentiment Signal: Sell

Current Market Cap: $4.15M

See more data about GCTK stock on TipRanks’ Stock Analysis page.